A new publication involving pasireotide appeared on August 21, 2026. The article, titled "Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature," was published in the journal Endocrine.
The review focuses on the management and safety considerations of somatostatin receptor ligands, a drug class that includes pasireotide, along with pegvisomant, in pregnant patients diagnosed with acromegaly. As a narrative review, the publication compiles existing literature on this topic.
No specific findings, outcomes, or safety conclusions from the review have been detailed here beyond its stated title and scope. Readers interested in the full analysis and any conclusions drawn by the authors should consult the original publication directly.
This brief reports only the existence and bibliographic details of this publication. For additional context on pasireotide, including its regulatory status and general background, readers can refer to the compound overview.